Abstract
The Accreditation Subcommittee of the EBMT regularly publishes special reports on current practice of haemopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders in Europe. Major changes have occurred since the first report was published in 1996. Haemopoietic stem cell transplantation today includes grafting with allogeneic and autologous stem cells derived from bone marrow, peripheral blood and cord blood. With reduced intensity conditioning regimens in allogeneic transplantation, the age limit has increased, permitting the inclusion of older patients. New indications have emerged such as autoimmune disorders and AL amyloidosis for autologous, and solid tumours for allogeneic transplants. The introduction of alternative therapies has challenged well-established indications such as imatinib for chronic myeloid leukaemia. An updated report with revised tables and operating definitions is presented here.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Schmitz N, Gratwohl A, Goldman JM . Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1996 and proposals for an operational classification. Bone Marrow Transplant 1996; 17: 471–477.
Goldman JM, Schmitz N, Niethammer D, Gratwohl A . Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1998. Bone Marrow Transplant 1998; 21: 1–7.
Gratwohl A, Hermans J, Baldomero H, Tichelli A, Goldman JM, Gahrton G . Indications for haemopoietic precursor cell transplants in Europe. Br J Haematol 1996; 92: 35–43.
Urbano-Ispizua A, Schmitz N, de Witte T, Frassoni F, Rosti G, Schrezenmeier H et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 2002; 29: 639–646.
Eapen M, Horowitz MM, Klein JP, Champlin RE, Loberiza Jr FR, Ringden O et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 2004; 22: 4872–4880.
Link H, Schmitz N, Gratwohl A, Goldman JM . Standards for specialist units undertaking blood and marrow stem cell transplants – recommendations from the EBMT. Bone Marrow Transplant 1995; 16: 733–763.
Joint Accreditation Committee. EBMT-EuroISHAGE (JACIE) Accreditation Manual (www.jacie.org).
Acknowledgements
We are grateful for the advice and helpful comments received from a number of individuals across Europe, specialising in the use of haemopoietic stem cell transplantation to treat patients with haematological disorders. We extend special thanks to G Gahrton, R Willemze, J Esteve, H Dombret, P Corradini, P Dreger, C Gisselbrecht, M Trneny, H Greinix, Y Beguin, CG Steward, A Fischer, A Cant, L Notarangelo, W Friedrich, and N Wulffraat.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Ljungman, P., Urbano-Ispizua, A., Cavazzana-Calvo, M. et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 37, 439–449 (2006). https://doi.org/10.1038/sj.bmt.1705265
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705265
Keywords
This article is cited by
-
Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019
Bone Marrow Transplantation (2019)
-
Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015
Bone Marrow Transplantation (2015)
-
Comparable outcome after single-antigen-mismatched versus matched unrelated donor haematopoietic cell transplantation
Journal of Cancer Research and Clinical Oncology (2015)
-
Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients
Bone Marrow Transplantation (2014)
-
The impact of center experience on results of reduced intensity: allogeneic hematopoietic SCT for AML. An analysis from the Acute Leukemia Working Party of the EBMT
Bone Marrow Transplantation (2013)